BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32881299)

  • 21. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
    Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
    Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
    Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
    Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics.
    Ochi N; Takeyama M; Miyake N; Fuchigami M; Yamane H; Fukazawa T; Nagasaki Y; Kawahara T; Nakanishi H; Takigawa N
    Exp Cell Res; 2023 Mar; 424(1):113503. PubMed ID: 36731710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.
    Yu S; Sha H; Qin X; Chen Y; Li X; Shi M; Feng J
    Oncogene; 2020 Mar; 39(13):2643-2657. PubMed ID: 32001818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.
    Wu Z; Bai F; Fan L; Pang W; Han R; Wang J; Liu Y; Yan X; Duan H; Xing L
    Hum Pathol; 2015 Dec; 46(12):1935-44. PubMed ID: 26475093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
    Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
    Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
    BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration.
    Nakajima T; Yasufuku K; Suzuki M; Hiroshima K; Kubo R; Mohammed S; Miyagi Y; Matsukuma S; Sekine Y; Fujisawa T
    Chest; 2007 Aug; 132(2):597-602. PubMed ID: 17573511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2.
    Wu CH; Zhang MS; Huang YL; Cheng WH; Lai JY; Hsieh MS; Liao WY
    Pathol Res Pract; 2024 May; 257():155304. PubMed ID: 38657557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
    Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learning.
    Li S; Luo T; Ding C; Huang Q; Guan Z; Zhang H
    Med Phys; 2020 Aug; 47(8):3458-3466. PubMed ID: 32416013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.
    Peng M; Weng YM; Liu HL; Yang GF; Yao Y; Han G; Song QB
    Biomed Res Int; 2018; 2018():7181368. PubMed ID: 29581983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
    Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
    PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.
    Li H; Cao J; Zhang X; Song X; Wang W; Jia S; Li Z; Jia H; Cao X; Zhou W; Lian J; Han S; Yang W; Xi Y; Lian S; Jing H
    Clin Exp Metastasis; 2017 Jan; 34(1):63-71. PubMed ID: 27888377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma.
    Nishimura T; Nakamura H; Yachie A; Hase T; Fujii K; Koizumi H; Naruki S; Takagi M; Matsuoka Y; Furuya N; Kato H; Saji H
    Sci Rep; 2020 Jul; 10(1):10881. PubMed ID: 32616892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.
    Akahori D; Inoue Y; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Suda T
    Sci Rep; 2021 Jul; 11(1):14999. PubMed ID: 34294857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
    J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.